勘误：鸦胆子碱H通过Notch3依赖的β-连环蛋白激活FOXO3a信号通路介导非小细胞肺癌中EGFR-TKI药物持久性。
Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling.
作者信息
Wu Jiahui, He Xiao, Xiong Ziwei, Shi Lingyu, Chen Daofeng, Feng Yulin, Wen Quan
机构信息
Pharmacy, Jiangxi University of Chinese Medicine, Jiangxi, China.
National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi, China.
出版信息
Front Oncol. 2024 Dec 3;14:1515205. doi: 10.3389/fonc.2024.1515205. eCollection 2024.
Abstract
[This corrects the article DOI: 10.3389/fonc.2022.855603.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2022.855603。]
相似文献
1
Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling.勘误：鸦胆子碱H通过Notch3依赖的β-连环蛋白激活FOXO3a信号通路介导非小细胞肺癌中EGFR-TKI药物持久性。
Front Oncol. 2024 Dec 3;14:1515205. doi: 10.3389/fonc.2024.1515205. eCollection 2024.
2
Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling.鸦胆子碱H通过Notch3依赖性β-连环蛋白激活FOXO3a信号通路介导非小细胞肺癌中EGFR-TKI药物持久性
Front Oncol. 2022 Apr 8;12:855603. doi: 10.3389/fonc.2022.855603. eCollection 2022.
3
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.Notch3 依赖性 β-连环蛋白信号通路介导 EGFR 突变型 NSCLC 对 EGFR-TKI 药物的耐药性。
Nat Commun. 2018 Aug 10;9(1):3198. doi: 10.1038/s41467-018-05626-2.
4
Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.Rab25 通过激活非小细胞肺癌中的β1 整合素/AKT/β-连环蛋白通路促进厄洛替尼耐药。
Cell Prolif. 2019 May;52(3):e12592. doi: 10.1111/cpr.12592. Epub 2019 Mar 7.
5
Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.β-连环蛋白抑制增强了 T790M 突变的 EGFR 突变型非小细胞肺癌中不可逆 EGFR-TKI 的抗癌作用。
J Thorac Oncol. 2015 Jan;10(1):93-101. doi: 10.1097/JTO.0000000000000353.
6
P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.P21 激活激酶 2 介导的β-连环蛋白信号通路促进 EGFR 突变型非小细胞肺癌中的癌症干细胞特性和奥希替尼耐药性。
Oncogene. 2022 Sep;41(37):4318-4329. doi: 10.1038/s41388-022-02438-z. Epub 2022 Aug 19.
7
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.勘误：基于一项组织和液体活检的临床多中心研究，携带TP53 R273C或KRAS G12V的EGFR T790M晚期非小细胞肺癌患者无法从奥希替尼中获益。
Front Oncol. 2023 Jun 27;13:1236311. doi: 10.3389/fonc.2023.1236311. eCollection 2023.
8
Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.勘误：循环中高浓度的音猬因子蛋白与接受酪氨酸激酶抑制剂治疗的EGFR突变晚期非小细胞肺癌的不良预后相关。
Front Oncol. 2022 Feb 9;12:852540. doi: 10.3389/fonc.2022.852540. eCollection 2022.
9
Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.E-钙黏蛋白/β-连环蛋白复合体的改变预测表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗反应不良。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S545-52. doi: 10.1245/s10434-013-2970-1. Epub 2013 Apr 12.
10
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.阻断 EGFR/AKT 信号增强 HER3 靶向药物 patritumab deruxtecan 在 EGFR 突变型非小细胞肺癌中的抗肿瘤活性。
Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17.
Zotero 插件